BRPI0916333A2 - piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociação - Google Patents
piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociaçãoInfo
- Publication number
- BRPI0916333A2 BRPI0916333A2 BRPI0916333A BRPI0916333A BRPI0916333A2 BR PI0916333 A2 BRPI0916333 A2 BR PI0916333A2 BR PI0916333 A BRPI0916333 A BR PI0916333A BR PI0916333 A BRPI0916333 A BR PI0916333A BR PI0916333 A2 BRPI0916333 A2 BR PI0916333A2
- Authority
- BR
- Brazil
- Prior art keywords
- piperazin
- trifluoromethyl
- receptor antagonists
- substituted pyridines
- dissociating dopamine
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- -1 piperazin-1-yl-trifluoromethyl-substituted pyridines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161576 | 2008-07-31 | ||
PCT/EP2009/059788 WO2010012758A1 (en) | 2008-07-31 | 2009-07-29 | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0916333A2 true BRPI0916333A2 (pt) | 2016-02-16 |
Family
ID=39817023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0916333A BRPI0916333A2 (pt) | 2008-07-31 | 2009-07-29 | piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociação |
Country Status (17)
Country | Link |
---|---|
US (1) | US8895562B2 (pt) |
EP (1) | EP2307374B1 (pt) |
JP (1) | JP5457450B2 (pt) |
KR (1) | KR101609218B1 (pt) |
CN (1) | CN102171189B (pt) |
AU (1) | AU2009275887B2 (pt) |
BR (1) | BRPI0916333A2 (pt) |
CA (1) | CA2730774C (pt) |
DK (1) | DK2307374T3 (pt) |
EA (1) | EA019048B1 (pt) |
ES (1) | ES2622161T3 (pt) |
HK (1) | HK1159083A1 (pt) |
HR (1) | HRP20170570T1 (pt) |
HU (1) | HUE033768T2 (pt) |
LT (1) | LT2307374T (pt) |
SI (1) | SI2307374T1 (pt) |
WO (1) | WO2010012758A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
JO2642B1 (en) | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
ES2400710T3 (es) | 2007-04-23 | 2013-04-11 | Janssen Pharmaceutica, N.V. | Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida |
CA2683111A1 (en) | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists |
CN101663291A (zh) * | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 作为快速离解的多巴胺2受体拮抗剂的吡啶衍生物 |
AU2009266001B2 (en) | 2008-07-03 | 2014-03-27 | Janssen Pharmaceutica Nv | Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists |
BRPI0916333A2 (pt) | 2008-07-31 | 2016-02-16 | Janssen Pharmaceutica Nv | piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociação |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3933823A (en) * | 1971-03-29 | 1976-01-20 | E. R. Squibb & Sons, Inc. | Isoxazolopyridine ketone derivatives |
DE2341965C3 (de) * | 1973-08-20 | 1979-01-25 | C.H. Boehringer Sohn, 6507 Ingelheim | 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen |
NO147672C (no) | 1975-09-23 | 1983-05-25 | Janssen Pharmaceutica Nv | Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider |
US4197304A (en) * | 1975-09-23 | 1980-04-08 | Janssen Pharmaceutica N.V. | N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides |
EG12406A (en) * | 1976-08-12 | 1979-03-31 | Janssen Pharmaceutica Nv | Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides |
DE3218482A1 (de) * | 1982-05-15 | 1983-11-17 | Bayer Ag, 5090 Leverkusen | Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
PT93060B (pt) | 1989-02-07 | 1995-12-29 | Sanofi Sa | Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem |
US5461053A (en) * | 1989-02-07 | 1995-10-24 | Sanofi | Pyridazine derivatives |
GB9216298D0 (en) | 1991-08-15 | 1992-09-16 | Ici Plc | Piperidine derivatives |
DK0737189T3 (da) | 1993-12-28 | 2000-03-06 | Upjohn Co | Heterocycliske forbindelser til behandling af CNS-forstyrrelser og cardiovaskulære forstyrrelser |
DE4425145A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung von Thiazol- und Thiadiazolverbindungen |
TW406075B (en) | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
US5753679A (en) | 1995-05-10 | 1998-05-19 | Hoffmann-La Roche Inc. | Benzyl-piperidine derivatives |
MY116093A (en) * | 1996-02-26 | 2003-11-28 | Upjohn Co | Azolyl piperazinyl phenyl oxazolidinone antimicrobials |
TW504510B (en) | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
HUP0003425A3 (en) | 1997-08-15 | 2002-02-28 | Pfizer Prod Inc | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives and pharmaceutical compositions containing the compounds |
KR100261139B1 (ko) | 1998-01-16 | 2000-08-01 | 황준수 | 신규한 알릴티오피리다진 유도체 및 그의 제조방법 |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
PL364625A1 (en) | 2001-02-23 | 2004-12-13 | Merck & Co, Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
JP4009251B2 (ja) | 2001-10-09 | 2007-11-14 | 杏林製薬株式会社 | 新規な4−(2−フロイル)アミノピペリジン、その合成中間体、その製造方法および医薬としてのその用途 |
GB0127832D0 (en) | 2001-11-20 | 2002-01-09 | Jagotec Ag | Method for the preparation of pharmaceutical nanosuspensions |
US7812035B2 (en) | 2001-12-11 | 2010-10-12 | Sepracor Inc. | 4-substituted piperidines, and methods of use thereof |
CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
WO2003066604A2 (en) | 2002-02-05 | 2003-08-14 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
AU2003213184A1 (en) | 2002-02-22 | 2003-09-09 | Pharmacia And Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
SE0201544D0 (sv) * | 2002-05-17 | 2002-05-17 | Biovitrum Ab | Novel compounds and thier use |
EP1543830B1 (en) * | 2002-09-26 | 2012-03-28 | Mandom Corporation | Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
AU2003239845A1 (en) * | 2003-05-07 | 2004-11-26 | Ifac Gmbh And Co.Kg | Compositions for the targetted release of fragrances and aromas |
KR101160858B1 (ko) | 2003-05-08 | 2012-07-02 | 가부시끼가이샤 닛신 세이훈 그룹 혼샤 | 소양 치료약으로서 유용한 4-(2-푸로일)아미노피페리딘류 |
WO2005005779A2 (en) | 2003-07-14 | 2005-01-20 | Genesis Mining Technologies (Pty) Ltd | Dual retention cutting arrangement |
BRPI0413048A (pt) | 2003-07-29 | 2006-10-17 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, e, método para o tratamento de distúrbios ou doenças relacionados com o receptor h3 da histamina |
DK1648874T3 (da) * | 2003-07-30 | 2012-01-23 | Xenon Pharmaceuticals Inc | Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer |
US7300932B2 (en) | 2003-08-07 | 2007-11-27 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
CN1871342B (zh) | 2003-10-24 | 2010-12-15 | 程涛 | p18对干细胞的调控 |
MXPA06009099A (es) | 2004-02-10 | 2007-02-02 | Johnson & Johnson | Piridazinona ureas como antagonistas de las integrinas alfa-4. |
WO2005090317A1 (en) | 2004-03-23 | 2005-09-29 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
EP1742932A1 (en) | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
US7820817B2 (en) | 2004-05-28 | 2010-10-26 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
EP1807085B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
ES2682282T3 (es) | 2004-10-29 | 2018-09-19 | Kalypsys, Inc. | Compuestos bicíclicos sustituidos con sulfonilo como moduladores de PPAR |
WO2006105993A2 (en) * | 2005-04-05 | 2006-10-12 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Method for shielding functional sites or epitopes on proteins |
ES2337727T3 (es) | 2005-06-20 | 2010-04-28 | Schering Corporation | Derivados de piperidina utiles como antagonistas de histamina h3. |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
WO2007130383A2 (en) | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
JP2010500391A (ja) | 2006-08-15 | 2010-01-07 | エフ.ホフマン−ラ ロシュ アーゲー | フェニル、ピリジン及びキノリン誘導体 |
CA2606658A1 (en) * | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
JO2642B1 (en) * | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
JO2849B1 (en) * | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
CN101663291A (zh) * | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 作为快速离解的多巴胺2受体拮抗剂的吡啶衍生物 |
ES2400710T3 (es) * | 2007-04-23 | 2013-04-11 | Janssen Pharmaceutica, N.V. | Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida |
CA2683111A1 (en) | 2007-04-23 | 2008-10-30 | Janssen Pharmaceutica N.V. | 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists |
US8299257B2 (en) * | 2007-09-20 | 2012-10-30 | Glaxo Group Limited | Compounds which have activity at M1receptor and their uses in medicine |
CA2727680A1 (en) * | 2008-06-13 | 2009-12-17 | Novartis Ag | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer |
AU2009266001B2 (en) * | 2008-07-03 | 2014-03-27 | Janssen Pharmaceutica Nv | Substituted 6- (1-piperazinyl) -pyridazines as 5-HT6 receptor antagonists |
BRPI0916333A2 (pt) | 2008-07-31 | 2016-02-16 | Janssen Pharmaceutica Nv | piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociação |
-
2009
- 2009-07-29 BR BRPI0916333A patent/BRPI0916333A2/pt not_active Application Discontinuation
- 2009-07-29 WO PCT/EP2009/059788 patent/WO2010012758A1/en active Application Filing
- 2009-07-29 KR KR1020117004503A patent/KR101609218B1/ko active IP Right Grant
- 2009-07-29 CA CA2730774A patent/CA2730774C/en active Active
- 2009-07-29 EP EP09802514.1A patent/EP2307374B1/en active Active
- 2009-07-29 ES ES09802514.1T patent/ES2622161T3/es active Active
- 2009-07-29 JP JP2011520499A patent/JP5457450B2/ja active Active
- 2009-07-29 CN CN2009801395994A patent/CN102171189B/zh active Active
- 2009-07-29 DK DK09802514.1T patent/DK2307374T3/en active
- 2009-07-29 EA EA201170256A patent/EA019048B1/ru not_active IP Right Cessation
- 2009-07-29 LT LTEP09802514.1T patent/LT2307374T/lt unknown
- 2009-07-29 SI SI200931644A patent/SI2307374T1/sl unknown
- 2009-07-29 HU HUE09802514A patent/HUE033768T2/en unknown
- 2009-07-29 AU AU2009275887A patent/AU2009275887B2/en not_active Ceased
- 2009-07-29 US US13/056,287 patent/US8895562B2/en active Active
-
2011
- 2011-12-09 HK HK11113345.2A patent/HK1159083A1/xx not_active IP Right Cessation
-
2017
- 2017-04-10 HR HRP20170570TT patent/HRP20170570T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2307374A1 (en) | 2011-04-13 |
ES2622161T3 (es) | 2017-07-05 |
HUE033768T2 (en) | 2017-12-28 |
JP2011529471A (ja) | 2011-12-08 |
CN102171189B (zh) | 2013-11-20 |
JP5457450B2 (ja) | 2014-04-02 |
EA201170256A1 (ru) | 2011-08-30 |
SI2307374T1 (sl) | 2017-05-31 |
EA019048B1 (ru) | 2013-12-30 |
US8895562B2 (en) | 2014-11-25 |
EP2307374B1 (en) | 2017-01-25 |
CA2730774A1 (en) | 2010-02-04 |
US20110130408A1 (en) | 2011-06-02 |
KR101609218B1 (ko) | 2016-04-05 |
HK1159083A1 (en) | 2012-07-27 |
AU2009275887B2 (en) | 2013-06-20 |
AU2009275887A1 (en) | 2010-02-04 |
DK2307374T3 (en) | 2017-05-01 |
KR20110041548A (ko) | 2011-04-21 |
CA2730774C (en) | 2016-09-13 |
HRP20170570T1 (hr) | 2017-06-16 |
LT2307374T (lt) | 2017-04-25 |
CN102171189A (zh) | 2011-08-31 |
WO2010012758A1 (en) | 2010-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821141A2 (pt) | Derivados de heteroarila como antagonistas do receptor de orexina | |
BRPI0910592A2 (pt) | antagonistas de receptor 2 de somatostatina | |
ZA201100866B (en) | Tripyridyl carboxamide orexin receptor antagonists | |
ZA201103156B (en) | Isonicotinamide orexin receptor antagonists | |
BRPI0817245A2 (pt) | Derivados e quinolina como antagonistas receptores de 5ht5a | |
BRPI0909157A2 (pt) | compostos heterocíclicos como antagonistas de receptores de adenosina | |
BRPI0910118A2 (pt) | antagonistas de receptores do glucagon | |
IL212545A0 (en) | Toll-like receptor 3 antagonists | |
BRPI0717937A2 (pt) | Compostos de pirazona como antagonistas do receptor mineralocorticóide | |
IL209264A0 (en) | Heteroaromatic monoamides as orexinin receptor antagonists | |
BRPI0814767A2 (pt) | Derivados de monoamida como antagonistas do receptor de orexina | |
BRPI0916333A2 (pt) | piridinas substituídas por piperazin-1-il-trifluorometila como antagonistas do receptor de dopamina 2 de rápida dissociação | |
DK2121630T3 (da) | Hurtigt dissocierende dopamin-2-receptor-antagonister | |
EP2365749A4 (en) | QUINOLONE ANTAGONISTS OF THE NEUROPEPTIDE S RECEPTOR | |
ZA201108724B (en) | Toll-like receptor 3 antagonists | |
SMT201300020B (it) | Derivati di isochinolinone come antagonisti dei recettori nk3 | |
BR112012003976A2 (pt) | antagonistas de receptor glyt1 carbocíclico | |
IL213982A0 (en) | Piperidine derivatives as nk3 receptor antagonists | |
EP2365748A4 (en) | IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS | |
BRPI0914779A2 (pt) | derivados de pirrolidina como antagonistas de receptor de nk2 | |
BRPI0914797A2 (pt) | derivados de éter de pirrolidina como antagonistas do receptor de nk3 | |
BRPI0921788A2 (pt) | derivados de 3-(benzilamino)-pirrolidina e sua aplicação como antagonistas de receptores de nk-3 | |
HK1169992A1 (en) | Pyrrolidine derivatives as nk - 3 receptor antagonists nk-3 | |
DK2257534T3 (da) | 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister | |
IL210927A0 (en) | 6-substituted benzoxazines as 5-ht-5a receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |